Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ian Read made chair of Pfizer in board reshuffle

This article was originally published in Scrip

Executive Summary

Pfizer has elected its current president and CEO, Ian Read, chair of the board, succeeding George Lorch who has been named lead independent director. Pfizer has also elected Dr Marc Tessier-Lavigne and Dr Helen Hobbs to its board. Dr Tessier-Lavigne is president of The Rockefeller University, and previously served as executive vice-president of research and CSO at Genentech. Dr Hobbs is an investigator for the Howard Hughes Medical Institute and a professor of internal medicine and molecular genetics at the University of Texas Southwestern Medical Center. She is also a director of its McDermott Center for Human Growth and Development. Dr Michael Brown, a Pfizer director since 1996, has announced his intention to retire from the board in April 2012.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts